½ÃÀ庸°í¼­
»óǰÄÚµå
1696283

¼¼°èÀÇ ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀå(2025-2033³â)

Global Hemostatic Matrix Market - 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°è ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 27¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇß°í, 2033³â¿¡´Â 39¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2033³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 4.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

ÁöÇ÷ ¸ÅÆ®¸¯½º´Â ¼ö¼ú Áß ÃâÇ÷À» Á¶ÀýÇϴ Ư¼ö ÀÇ·á Á¦Ç°ÀÔ´Ï´Ù. ´ëºÎºÐÀÇ °æ¿ì À¯µ¿¼º Á©¶óƾ ¸ÅÆ®¸¯½º¿Í Æ®·Òºó ¼ººÐÀÌ °áÇյǾî Ç÷¾× ÀÀ°í¸¦ ºü¸£°Ô ÃËÁøÇÕ´Ï´Ù. ÀÌ Á¶ÇÕÀº ¼ÒÀÛ, °áÂû, ºÀÇÕ°ú °°Àº ÀüÅëÀûÀÎ ¹æ¹ýÀÌ È¿°úÀûÀÌÁö ¾ÊÀº °æ¿ì, ¿¹¸¦ µé¾î Ç¥¸éÀûÀÌ ³Ð°Å³ª ÃâÇ÷ ºÎÀ§¿¡ Á¢±ÙÇϱ⠾î·Á¿î °æ¿ì µî¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

¿Ü°ú ¼ö¼ú, ƯÈ÷ ¿Ü»ó Ä¡·á Áõ°¡´Â ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, ±³Åë »ç°í·Î ÀÎÇØ ¿¬°£ 119¸¸ ¸í ÀÌ»óÀÇ »ç¶÷µéÀÌ ¸ñ¼ûÀ» ÀÒ°í ÀÖÀ¸¸ç, À̵é Áß »ó´ç¼ö´Â ½Å¼ÓÇÑ ¿Ü°úÀû °³ÀÔÀÌ ÇÊ¿äÇÑ ½É°¢ÇÑ ÃâÇ÷À» °æÇèÇϰí ÀÖ½À´Ï´Ù.

À̴ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ ÃâÇ÷À» Á¶ÀýÇÏ´Â °ÍÀÌ Áß¿äÇÑ ¿Ü»ó ¼ö¼ú¿¡¼­ È¿°úÀûÀÎ ÁöÇ÷Á¦ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç° ¼ö¿ä´Â ¿Ü»ó °ü·Ã ¼ö¼ú °Ç¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ƯÈ÷ »ç°íÀ²ÀÌ ³ôÀº Áö¿ªÀ̳ª ÀÀ±ÞÀÇ·á ÀÎÇÁ¶ó°¡ ¹ß´ÞÇÑ Áö¿ª¿¡¼­ ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÁöÇ÷ ±â¼úÀÇ ¹ßÀüÀ¸·Î º¸´Ù È¿°úÀûÀÌ°í ´ÙÀç´Ù´ÉÇÑ Á¦Ç°ÀÌ °³¹ßµÇ¾î ¼ö¼úÀÇ È¿À²¼º°ú ȯÀÚÀÇ ¾ÈÀü¼ºÀÌ ¸ðµÎ Çâ»óµÇ°í ÀÖ´Â °Íµµ ÀÌ·¯ÇÑ ¼ö¿ä¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ

¼ö¼ú °Ç¼ö Áõ°¡

¼¼°è ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀåÀº ¿©·¯ °¡Áö Áß¿äÇÑ ÃËÁø¿äÀο¡ ÀÇÇØ È®´ëµÇ°í ÀÖÀ¸¸ç, ±× ÁÖ¿ä ¿øÀÎÀº ¿Ü°ú ¼ö¼ú Áõ°¡ÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î °í·ÉÈ­°¡ ÁøÇàµÊ¿¡ µû¶ó °üÀý ġȯ¼ú, ½ÉÇ÷°ü ¼ö¼ú°ú °°Àº ¼ö¼úÀ» ÇÊ¿ä·Î ÇÏ´Â ³ëÈ­ °ü·Ã °Ç°­ ¹®Á¦ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹öÁö´Ï¾Æ ´ëÇÐÀÇ ´º½º¿¡ µû¸£¸é, 2030³â±îÁö ¹Ì±¹ Àα¸ÀÇ 20%°¡ 65¼¼ ÀÌ»óÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ·¯ÇÑ À¯ÇüÀÇ ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â º¹ÀâÇÑ ¼ö¼ú Áß ÃâÇ÷À» Á¶ÀýÇÏ´Â µ¥ Áß¿äÇÑ ÁöÇ÷ ¸ÅÆ®¸¯½º Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àα¸ Åë°èÇÐÀû ¿äÀÎ ¿Ü¿¡µµ ¾÷°è ÁÖ¿ä ±â¾÷µéÀÇ Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã°¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿Ã¸²Çª½º´Â 2023³â 4¿ù ¼ÒÈ­°ü ¼ö¼ú¿ëÀ¸·Î ¼³°èµÈ ÁöÇ÷Á¦ Á¦Ç°±ºÀÎ EndoClot Æ÷Æ®Æú¸®¿À¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ¿©±â¿¡´Â ÁöÇ÷À» µ½°í ³»½Ã°æ Á¡¸·ÇÏ ¹Ú¸®¼ú(ESD) ¹× ³»½Ã°æ Á¡¸·ÇÏ ÀýÁ¦¼ú(EMR)°ú °°Àº ¼ö¼ú¿¡ ƯÈ÷ À¯¿ëÇÑ Á¡¸·ÇÏ ÁÖÀÔ¾×À» Á¦°øÇÏ´Â Á¦Ç°ÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ Á¦Ç°µéÀº ³»½Ã°æ ¼ö¼ú ½Ã Á¡¸·ÀÇ ºÎÇ®¾î ¿À¸¥ »óŸ¦ ¿À·§µ¿¾È À¯ÁöÇÏ¿© ¼ö¼úÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» ³ôÀÌ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

ÀÌ·¯ÇÑ Àα¸ Åë°èÇÐÀû Ãß¼¼¿Í ±â¼ú Çõ½ÅÀº ´õ ¸¹Àº ¼ö¼úÀÌ ½ÃÇàµÇ°í, °í±ÞÀÇ È¿°úÀûÀÎ ÃâÇ÷ Á¦¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼¼°è ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå µ¿·ÂÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ðµç ¿äÀεéÀÌ ¼¼°è ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀåÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù.

Á¦Ç° ¸®ÄÝ

Á¦Ç° ¸®ÄÝÀº ¸·´ëÇÑ ±ÝÀüÀû ¼Õ½Ç°ú ºê·£µå ÆòÆÇ ¼Õ»óÀ¸·Î À̾îÁú ¼ö ÀÖ°í, °¡Àå Áß¿äÇÑ °ÍÀº ȯÀÚÀÇ ¾ÈÀü¿¡ À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö Àֱ⠶§¹®¿¡ Àü ¼¼°è ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀåÀÇ Å« ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸®ÄÝÀº Á¦Ç° »ç¿ë Áß ¶Ç´Â ǰÁú °ü¸® °úÁ¤À» ÅëÇØ ¾ÈÀü¼º ¹× À¯È¿¼º ¹®Á¦°¡ È®ÀÎµÈ °æ¿ì Á¾Á¾ ¹ß»ýÇÕ´Ï´Ù. ÁöÇ÷Á¦°¡ È¿°ú°¡ ¾ø°Å³ª, ¿À¿°µÇ¾ú°Å³ª, ±âŸ ¹®Á¦°¡ ÀÖ´Â °ÍÀ¸·Î ÆÇ¸íµÉ °æ¿ì, ÃâÇ÷ Á¶Àý ½ÇÆÐ³ª °¨¿°°ú °°Àº À¯ÇØÇÑ ¼ö¼ú °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ¾î ȯÀÚÀÇ °Ç°­À» À§ÇùÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2024³â 9¿ù Baxter Healthcare´Â ¾ÈÁ¤¼º Å×½ºÆ® Áß ¹ß°ßµÈ ¹®Á¦·Î ÀÎÇØ Tisseel Lyo Fibrin Sealant KitsÀÇ Æ¯Á¤ ¹èÄ¡¿¡ ´ëÇÑ ÀÚ¹ßÀû ¸®ÄÝÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Å°Æ®´Â ´Ù¾çÇÑ ¼ö¼ú¿¡ »ç¿ëµÇ¸ç, À̹ø ¸®ÄÝÀº ƯÈ÷ ȯÀÚ °á°ú¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÇ·á±â±â¿¡ ´ëÇÑ Á¦Ç° ǰÁú°ú ¾ÈÀü¼ºÀ» º¸ÀåÇÏ´Â °ÍÀÌ ¾ó¸¶³ª Áß¿äÇÑÁö Àß º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸®ÄÝÀº °áÇÔÀÌ ÀÖÀ» °æ¿ì ¼ö¼ú Áß ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö Àֱ⠶§¹®¿¡ ÁöÇ÷ Á¦Ç°°ú °ü·ÃµÈ ÀáÀçÀû À§ÇèÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ À§¿Í °°Àº ¿äÀεéÀÌ ¼¼°è ÁöÇ÷Àç ½ÃÀåÀÇ ÀáÀçÀû ¼ºÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå ¿ªÇÐ, Áö¿ª ¹× ºÎ¹® ºÐ¼®, °æÀï ±¸µµ, ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¼­·Ð°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ÀλçÀÌÆ®¿Í Áß¿ä »çÇ×

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®¿Í Àü·«Àû Æ÷ÀÎÆ®
  • ÁÖ¿ä µ¿Çâ°ú ÇâÈÄ ¿¹Ãø
  • ¹ßÃé : Á¦Ç° À¯Çüº°
  • ¹ßÃé : Çüź°
  • ¹ßÃé : ¿ëµµº°
  • ¹ßÃé : ÃÖÁ¾»ç¿ëÀÚº°
  • ¹ßÃé : Áö¿ªº°

Á¦3Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • ¿µÇ⠺м®

Á¦4Àå Àü·«Àû ÀλçÀÌÆ®¿Í »ê¾÷ Àü¸Á

  • ½ÃÀå ¸®´õ¿Í ¼±±¸ÀÚ
    • ½ÅÈï ¼±±¸ÀÚ¿Í Àú¸í ±â¾÷
    • ±âÁ¸ ¸®´õ¿Í °¡Àå ¸¹ÀÌ ÆÇ¸ÅµÇ´Â ºê·£µå
    • ½ÃÀå ¸®´õ¿Í ±âÁ¸ Á¦Ç°
  • CXOÀÇ °ßÇØ
  • ÃֽйßÀü°ú Break through
  • »ç·Ê ¿¬±¸/ÁøÇàÁßÀÎ Á¶»ç
  • ±ÔÁ¦¿Í »óȯ »óȲ
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • PorterÀÇ Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • ƯÇ㠺м®
  • SWOT ºÐ¼®
  • ¹ÌÃæÁ· ¿ä±¸¿Í °¸
  • ½ÃÀå ÁøÀÔ ¹× È®ÀåÀ» À§ÇÑ ±ÇÀå Àü·«
  • ½Ã³ª¸®¿À ºÐ¼® : º£½ºÆ® ÄÉÀ̽º, ±âº» ÄÉÀ̽º, ¿ö½ºÆ® ÄÉÀ̽º ¿¹Ãø
  • °¡°Ý ºÐ¼®°ú °¡°Ý µ¿Çâ
  • KOL(Key Opinion Leader)

Á¦5Àå ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀå : Á¦Ç° À¯Çüº°

  • Á©¶óƾ ±â¹Ý ÁöÇ÷ ¸ÅÆ®¸¯½º
  • Äݶó°Õ ±â¹Ý ÁöÇ÷ ¸ÅÆ®¸¯½º
  • Æ®·Òºó ±â¹Ý ÁöÇ÷ ¸ÅÆ®¸¯½º
  • º¹ÇÕ ÁöÇ÷ ¸ÅÆ®¸¯½º
  • ±âŸ

Á¦6Àå ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀå : Çüź°

  • °Ö
  • Æû
  • ºÐ¸»
  • ÆäÀ̽ºÆ®

Á¦7Àå ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀå : ¿ëµµº°

  • ¿Ü°ú ¼ö¼ú
    • ½ÉÇ÷°ü ¼ö¼ú
    • Á¤Çü¿Ü°ú ¼ö¼ú
    • ³ú½Å°æ ¼ö¼ú
    • ÀϹݿܰú ¼ö¼ú
    • ºÎÀΰú ¼ö¼ú
    • ºñ´¢±â°ú ¼ö¼ú
    • ±âŸ
  • ¿Ü»ó Äɾî
  • â»ó °ü¸®
  • ±âŸ

Á¦8Àå ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ¿Ü»ó ¼¾ÅÍ
  • ±âŸ

Á¦9Àå ÁöÇ÷ ¸ÅÆ®¸¯½º ½ÃÀå : Áö¿ªº°, ½ÃÀå ºÐ¼®°ú ¼ºÀå ±âȸ

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¸ß½ÃÄÚ
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ¿Í ½ÃÀå Æ÷Áö¼Å´×

  • °æÀï ±¸µµ °³¿ä¿Í ÁÖ¿ä ½ÃÀå ±â¾÷
  • ½ÃÀå Á¡À¯À² ºÐ¼®°ú Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·«Àû ÆÄÆ®³Ê½Ê ¹× ÀμöÇÕº´(M&A)
  • Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í Çõ½Å ÁÖ¿ä ¹ßÀü
  • ±â¾÷ º¥Ä¡¸¶Å·

Á¦11Àå ±â¾÷ °³¿ä

  • Pfizer Inc.
  • Ethicon(Johnson & Johnson)
  • Baxter International Inc.
  • Becton, Dickinson and Company(BD)
  • B. Braun SE
  • Integra LifeSciences Corporation.
  • CryoLife, Inc.(Artivion, Inc)
  • Advanced Medical Solutions Group plc
  • Aegis Lifesciences
  • Teleflex Incorporated.
  • HLB Cell

Á¦12Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý

Á¦13Àå ºÎ·Ï

LSH 25.04.15

The global hemostatic matrix market reached US$ 2.74 billion in 2024 and is expected to reach US$ 3.91 billion by 2033, growing at a CAGR of 4.8% during the forecast period of 2025-2033.

A hemostatic matrix is a specialized medical product that controls bleeding during surgical procedures. It often combines a flowable gelatin matrix with a thrombin component, working together to facilitate rapid blood clotting. This combination is particularly valuable when traditional methods like cautery, ligatures, or sutures might not be effective, such as in cases involving large surface areas or difficult-to-access bleeding sites.

The growing number of surgical procedures, especially in trauma care, is a key driver for the hemostatic matrix market. For example, according to World Health Organization (WHO) data, road traffic accidents claim the lives of over 1.19 million people annually, with many of these victims experiencing severe bleeding that requires prompt surgical intervention.

This highlights the increasing need for effective hemostatic agents in trauma surgeries, where bleeding control is crucial for improving patient outcomes. The demand for such products is expected to grow as the number of trauma-related surgeries rises, particularly in regions with high rates of accidents or where emergency medical infrastructure is developing. This demand is further fueled by advancements in hemostatic technology, which has led to the development of more effective and versatile products, enhancing both surgical efficiency and patient safety.

Market Dynamics: Drivers & Restraints

Increasing Number of Surgical Procedures

The global hemostatic matrix market is expanding due to several key drivers, with the rise in surgical procedures being a primary factor. As the global population ages, there is an increasing prevalence of age-related health issues that necessitate surgeries, such as joint replacements and cardiovascular procedures. According to University of Virginia news, it is projected that by 2030, 20% of the U.S. population will be over the age of 65, which will significantly increase the demand for these types of surgeries This trend is expected to drive the need for hemostatic matrix products, which are crucial for controlling bleeding during complex surgical procedures.

In addition to demographic factors, innovative product launches by key players in the industry are further fueling market growth. For example, in April 2023, Olympus introduced its EndoClot portfolio, a line of hemostatic agents designed for gastrointestinal procedures. This includes products that aid in hemostasis and provide a submucosal injection solution, which is particularly beneficial for procedures such as endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR). These products help maintain a long-lasting mucosal lift during endoscopic procedures, enhancing both surgical effectiveness and safety.

Together, these demographic trends and technological innovations are key factors driving the growth of the global hemostatic matrix market, as more surgical procedures are performed and demand for advanced, effective bleeding control solutions increases. All these factors demand the global hemostatic matrix market.

Product Recalls

Product recalls represent a significant restraint in the global hemostatic matrix market, as they can lead to substantial financial losses, damage to brand reputation, and, most importantly, pose risks to patient safety. These recalls often occur when safety or efficacy issues are identified during product usage or through quality control processes. If a hemostatic agent is found to be ineffective, contaminated, or otherwise compromised, it can lead to adverse surgical outcomes such as uncontrolled bleeding or infections, which jeopardize patient health.

For example, in September 2024, Baxter Healthcare issued a voluntary recall for certain batches of its Tisseel Lyo Fibrin Sealant Kits due to issues detected during stability studies. These kits are used in various surgical procedures, and the recall underscores the importance of ensuring product quality and safety, especially for medical devices that directly affect patient outcomes. Such recalls highlight the potential risks associated with hemostatic products, as any defect can result in severe complications during surgeries. Thus, the above factors could be limiting the global hemostatic matrix market's potential growth.

Segment Analysis

The global hemostatic matrix market is segmented based on product type, form, application, end-user, and region.

Product Type:

The thrombin-based hemostatic matrix segment in product type is expected to dominate the global hemostatic matrix market with the highest market share

The thrombin-based hemostatic matrix products are designed to control bleeding during surgical procedures, particularly in situations where traditional methods, such as ligatures or cautery, are either impractical or ineffective. The matrix combines a gelatin-based substance with thrombin, an enzyme that promotes clot formation.

This combination enhances hemostasis through two primary mechanisms: mechanical action, where the matrix physically compresses the bleeding area, and biochemical action, where thrombin catalyzes the formation of a clot. The effectiveness of thrombin-based hemostatic matrices in controlling bleeding makes them invaluable across various clinical settings, particularly in cardiovascular, orthopedic, and trauma surgeries. These matrices are especially crucial in situations where surgeons need immediate bleeding control and other methods cannot achieve the desired results.

Research and development in the segment have further solidified its market position. For instance, a meta-analysis from an NCBI study in October 2023 focused on the effectiveness of Floseal, a thrombin-based hemostatic matrix, in minimizing blood loss during total knee arthroplasty (TKA). The study highlighted ongoing debates in the medical community about the matrix's ability to reduce transfusion requirements during TKA surgeries.

While some randomized controlled trials (RCTs) have demonstrated their benefits, other studies have questioned their overall effectiveness. Nevertheless, the growing body of research in this area continues to reinforce the relevance of thrombin-based matrices in surgery, especially for high-risk or complex procedures. This focus on clinical efficacy and product development by key industry players is expected to drive continued growth in the thrombin-based hemostatic matrix segment, ensuring its dominance within the broader hemostatic matrix market.

Geographical Analysis

North America is expected to hold a significant position in the global hemostatic matrix market with the highest market share

In the North America region hemostatic matrix market is due to several critical factors. A major driver is the rising prevalence of chronic diseases, particularly cardiovascular diseases (CVD), diabetes, and obesity, all of which often require surgical intervention.

As CVD rates continue to increase, the demand for cardiovascular surgeries such as coronary artery bypass grafting (CABG), valve replacements, and other cardiac procedures also rises. According to the American Heart Association, in July 2024, more than 184 million people are expected to be affected by some form of CVD by 2050, and the total costs related to CVD are projected to triple to approximately $1.8 trillion. This trend underscores the growing need for effective hemostatic solutions to control bleeding during these complex procedures, further driving demand for hemostatic matrix products.

Additionally, North America benefits from a robust healthcare infrastructure, the presence of numerous key industry players, and strong government initiatives and regulatory support. This combination facilitates the rapid adoption of innovative medical technologies.

A notable example of innovation in the region is the approval of ETHIZIA, a hemostatic sealing patch by Ethicon, a Johnson & Johnson MedTech company. In November 2023, Ethicon received approval for ETHIZIA, a product designed to address challenging bleeding situations during surgeries. The patch is unique for its synthetic polymer technology, which makes it effective on both sides, allowing it to be used in both open and minimally invasive surgeries. ETHIZIA demonstrated the ability to stop bleeding in 80% of patients within 30 seconds, which is significantly faster than traditional fibrin sealant patches

These factors, along with continued investment in product development, clinical trials, and regulatory approvals, are solidifying North America's position as a dominant force in the hemostatic matrix market. The region's well-established healthcare system and commitment to medical innovation make it a primary hub for the adoption of advanced hemostatic solutions.

Competitive Landscape

The major global players in the hemostatic matrix market include Pfizer Inc., Ethicon (Johnson & Johnson), Baxter International Inc., Becton, Dickinson and Company (BD), B. Braun SE, Integra LifeSciences Corporation., CryoLife, Inc. (Artivion, Inc), Advanced Medical Solutions Group plc, Aegis Lifesciences, Teleflex Incorporated., and HLB Cell among others.

Key Developments

  • In July 2023, Baxter International Inc. launched the PERCLOT Absorbable Hemostatic Powder in the United States, enhancing its portfolio of surgical innovations. PERCLOT is a passive, absorbable hemostatic agent designed for patients with intact coagulation systems. It is primarily used to manage mild bleeding during various surgical procedures, offering a non-invasive solution to control bleeding without requiring additional interventions.
  • In March 2023, Axio Biosolutions, a med-tech company based in Bengaluru, achieved a significant milestone by receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Ax-Surgi Surgical Hemostat. This approval marks Ax-Surgi as the first chitosan-based hemostatic agent cleared for use in controlling severe surgical bleeding, positioning it as a breakthrough product in managing high-risk bleeding situations during surgeries.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global hemostatic matrix market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Form
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Number of Surgical Procedures
      • 3.1.1.2. Innovations in Hemostatic Products
    • 3.1.2. Restraints
      • 3.1.2.1. Product Recalls
      • 3.1.2.2. Risk of Adverse Reactions
    • 3.1.3. Opportunity
      • 3.1.3.1. Growth in Minimally Invasive Surgeries
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Hemostatic Matrix Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index By Product Type
  • 5.2. Gelatin-based Hemostatic Matrix*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Collagen-based Hemostatic Matrix
  • 5.4. Thrombin-based Hemostatic Matrix
  • 5.5. Combination Hemostatic Matrix
  • 5.6. Others

6. Hemostatic Matrix Market, By Form

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 6.1.2. Market Attractiveness Index By Form
  • 6.2. Gel*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Foam
  • 6.4. Powder
  • 6.5. Paste

7. Hemostatic Matrix Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index By Application
  • 7.2. Surgical Procedures*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Cardiovascular Surgery
    • 7.2.4. Orthopedic Surgery
    • 7.2.5. Neurosurgery
    • 7.2.6. General Surgery
    • 7.2.7. Gynecological Surgery
    • 7.2.8. Urology Surgery
    • 7.2.9. Others
  • 7.3. Trauma Care
  • 7.4. Wound Care
  • 7.5. Others

8. Hemostatic Matrix Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Trauma Centers
  • 8.5. Others

9. Hemostatic Matrix Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. Latin America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Mexico
      • 9.4.7.2. Brazil
      • 9.4.7.3. Argentina
      • 9.4.7.4. Rest of Latin America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Pfizer Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals, etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Ethicon (Johnson & Johnson),
  • 11.3. Baxter International Inc.
  • 11.4. Becton, Dickinson and Company (BD)
  • 11.5. B. Braun SE
  • 11.6. Integra LifeSciences Corporation.
  • 11.7. CryoLife, Inc. (Artivion, Inc)
  • 11.8. Advanced Medical Solutions Group plc
  • 11.9. Aegis Lifesciences
  • 11.10. Teleflex Incorporated.
  • 11.11. HLB Cell

LIST NOT EXHAUSTIVE

12. Assumptions and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦